Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Cyduct Diagnostics Inc

Healthcare US CYDX

0.403USD
0.00(0%)

Last update at 2026-06-19T20:00:00Z

Day Range

0.400.40
LowHigh

52 Week Range

0.202.90
LowHigh

Fundamentals

  • Previous Close 0.40
  • Market Cap3.20M
  • Volume160
  • P/E Ratio0.79
  • Dividend Yield-%
  • EBITDA-0.50235M
  • Revenue TTM0.34M
  • Revenue Per Share TTM1.94
  • Gross Profit TTM 0.21M
  • Diluted EPS TTM0.77

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -0.41361M -0.41803M -0.47614M -0.42049M -0.37203M
Minority interest - - - - -
Net income -0.41361M -0.41803M -0.47274M -0.42049M -0.37203M
Selling general administrative - - - - -
Selling and marketing expenses - - - - -
Gross profit 0.05M 0.06M 0.08M 0.06M 0.12M
Reconciled depreciation - - - - -
Ebit - - -0.66973M -0.40355M -0.57713M
Ebitda -0.36322M -0.37891M -0.44125M -0.16699M -0.37083M
Depreciation and amortization - - 0.23M 0.24M 0.21M
Non operating income net other - - - - -
Operating income -0.36322M -0.37891M -0.44465M -0.40355M -0.37083M
Other operating expenses 0.43M 0.46M 0.56M 0.50M 0.53M
Interest expense 0.05M 0.04M 0.03M 0.02M 0.00120M
Tax provision - - - - -
Interest income - - - - -
Net interest income - - - - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - -0.22848M -0.23656M -0.20630M
Total revenue 0.07M 0.08M 0.12M 0.09M 0.16M
Total operating expenses 0.41M 0.44M 0.52M 0.47M 0.49M
Cost of revenue 0.02M 0.03M 0.04M 0.03M 0.05M
Total other income expense net -0.05040M -0.03913M -0.03149M -0.01694M -0.00120M
Discontinued operations - - - - -
Net income from continuing ops - - - - -
Net income applicable to common shares - - - - -
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 0.04M 0.05M 0.08M 0.30M 0.07M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets - - - 0.00068M -
Total liab 2.85M 2.45M 2.10M 1.85M 1.20M
Total stockholder equity -2.80867M -2.39506M -2.02344M -1.55069M -1.13020M
Deferred long term liab - - - - -
Other current liab 1.92M 0.06M 1.46M 0.00000M 0.00000M
Common stock 0.00514M 0.00514M 0.00514M 0.00514M 0.00514M
Capital stock - - - - -
Retained earnings -14.55199M -14.13838M -13.71694M -13.24420M -12.82371M
Other liab - - - - -
Good will - - - - -
Other assets - - - - -
Cash 0.00121M 0.03M 0.05M 0.27M 0.02M
Cash and equivalents - - - - -
Total current liabilities 2.22M 1.86M 1.81M 1.41M 1.14M
Current deferred revenue - 1.61M - 0.00000M 0.00000M
Net debt 0.71M 0.64M 0.52M 0.25M 0.12M
Short term debt 0.09M 0.08M 0.28M 0.08M 0.08M
Short long term debt - - - - -
Short long term debt total 0.71M 0.67M 0.57M 0.52M 0.14M
Other stockholder equity 11.74M 11.74M -0.00514M -0.00514M -0.00514M
Property plant equipment - - - - -
Total current assets 0.04M 0.05M 0.08M 0.30M 0.07M
Long term investments - - - - -
Net tangible assets - - - - -
Short term investments - - - - -
Net receivables 0.02M 0.01M 0.01M 0.00765M 0.03M
Long term debt - - - - -
Inventory 0.02M 0.01M 0.01M 0.02M 0.02M
Accounts payable 0.21M 0.12M 0.07M 1.33M 1.06M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - 11.69M 11.69M 11.69M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - -
Deferred long term asset charges - - - - -
Non current assets total - - - - -
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments - - - - -
Change to liabilities - - - - -
Total cashflows from investing activities - -0.00019M - - -
Net borrowings - - - - -
Total cash from financing activities 0.04M 0.15M 0.05M 0.38M -
Change to operating activities - - - - -
Net income -0.41361M -0.41803M -0.47274M -0.42049M -0.37203M
Change in cash -0.02859M -0.02502M -0.21685M 0.25M 0.00055M
Begin period cash flow 0.03M 0.05M 0.27M 0.02M 0.02M
End period cash flow 0.00121M 0.03M 0.05M 0.27M 0.02M
Total cash from operating activities -0.07198M -0.17483M -0.26685M -0.12773M -0.05795M
Issuance of capital stock - - - - -
Depreciation - - - - -
Other cashflows from investing activities - -0.00019M -0.00000M - -
Dividends paid - - - - -
Change to inventory -0.00558M 0.00228M 0.00220M 0.00696M -0.01183M
Change to account receivables -0.00595M -0.00120M -0.00391M 0.02M -0.01791M
Sale purchase of stock - - - - -
Other cashflows from financing activities - -0.00019M 0.05M 0.38M -
Change to netincome - - - - -
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.34M 0.24M 0.21M 0.29M 0.25M
Stock based compensation - - - - -
Other non cash items - - -0.02221M -0.29344M 0.06M
Free cash flow -0.07198M -0.17483M -0.26685M -0.12773M -0.05795M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x)
CYDX
Cyduct Diagnostics Inc		 - -% 0.40 0.79 - 9.27 -
ABT
Abbott Laboratories		 -0.58 0.66% 87.83 25.97 17.24 3.57 3.20 3.81 16.75
SYK
Stryker Corporation		 -3.11 1.01% 304.69 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC		 -0.07 0.09% 79.27 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp		 -0.96 2.12% 44.33 31.49 17.24 4.41 3.65 4.88 19.19

Reports Covered

Stock Research & News

View All

Profile

CYduct Diagnostics, Inc., a healthcare company, develops, produces, and markets medical devices for the assessment, identification, diagnosis and treatment of breast cancer. The company offers HALO system, a noninvasive device that utilizes proprietary technology to obtain breast fluid; and MammoView, a fiberoptic technology with the ability to view and collect cells and other abnormalities. It also provides women and clinicians with technology that will lead the Intraductal approach to breast cancer and improvement in breast healthcare. The company was formerly known as Solos Endoscopy, Inc. and changed its name to CYduct Diagnostics, Inc. in December 2020. CYduct Diagnostics, Inc. was incorporated in 1986 and is based in Westport, Connecticut.

Cyduct Diagnostics Inc

1698 Post Rd. E, Westport, CT, United States, 06880

Key Executives

Name Title Year Born
Mr. Dom L. Gatto Pres, CEO, Sec., Treasurer & Chairman 1962
Mr. Fred V. Schiemann CPA CFO & Director 1952
Mr. Gerald Schwebel Operations Mang. NA
Ms. J. Amanda Segersten Sec. NA
Mr. Dom L. Gatto President, CEO, Secretary, Treasurer & Chairman 1962
Mr. Gerald Schwebel Operations Manager NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions